pharmaceutical-investing FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
pharmaceutical-investing FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL 9
